WHEAT RIDGE, Colo.--(BUSINESS WIRE)--April 6, 2006--GeneThera (OTCBB:GTHA - News) announces that its Purivax(TM) technology -- a large-scale process for highly purified and high viral titer Adenovirus and AAV recombinant vectors, would enable fast track development of Adenovirus and AAV-based recombinant DNA vaccines for diseases such as the Avian Flu (commonly called Bird Flu).
